There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF), both in clinical trials and in 'real-world' practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. This paper aims to utilize several 'real-life' cases to illustrate several strategies that may help to optimize clinical practice.
Intern Med J